Simplifying CRISPR Therapeutic Manufacturing: Practical Solutions to Accelerate and Simplify Manufacturing

The rise of CRISPR-based therapies has reshaped the biopharmaceutical landscape, offering unprecedented opportunities for innovation and platform advancement. Yet for many organizations, the road from early development to commercialization remains complex.

One of the most pressing challenges lies in the management of multiple CDMOs and timelines. Programs often depend on multiple vendors, requiring teams to manage cycle times across different providers, align scarce slot availability and mitigate shipment risks between facilities. Each of these factors can introduce costly delays, increase regulatory complexity and ultimately extend the time needed to bring new therapies to market.

This webinar will provide attendees with practical strategies to address these challenges head-on. By highlighting the consolidated capabilities in nucleic acid manufacturing — including sgRNA, pDNA, mRNA, LNP formulation and fill/finish — the featured speakers will explore how program leaders can simplify coordination, reduce risks and improve readiness for scale-up and commercialization.

Key topics will include:

• Understanding how an end-to-end workflow improves overall project timelines and simplifies supply chain management
• Strategies to ensure slot availability aligns across critical manufacturing steps
• Best practices for minimizing shipment risks and maintaining product integrity across geographies
• The benefits of an integrated approach that unifies expertise, facilities and technologies under one framework

This webinar is designed for pharma and biopharma professionals responsible for development strategy, outsourcing and manufacturing coordination. Attendees will leave with actionable insights on how to streamline CRISPR therapeutic manufacturing, optimize regulatory preparedness and strengthen commercial readiness — tools they can apply within their own organizations.

Register for this webinar to learn how simplifying supply chain management can accelerate the advancement of CRISPR-based therapies, reduce risk and ultimately bring therapies to market faster.

Speakers

Jessica Madigan, Director Business Development, Nucleic Acid Modalities, BIOVECTRA

Jessica Madigan has a BSc in Chemistry and has over 15 years of experience in nucleic acid manufacturing and development. She has played a key role at a start-up CDMO, contributing to the successful launch of mRNA, plasmid, capping analogs and modified nucleotide products. Jessica also holds a Project Management Professional (PMP) Certification and successfully managed over 30 API manufacturing projects for mRNA early-phase clinical trials. Since joining BIOVECTRA in 2022, Jessica has supported business development efforts for pDNA, mRNA, LNP formulation and fill/finish services.

Message Presenter

Amanda Haas, Business Development Manager, Agilent Technologies

Amanda Haas is a Business Development Manager at Agilent Technologies with over 20 years of experience in life sciences and biotechnology. She has been with Agilent for four years, growing gene editing therapeutic services, using market research, voice of the customer and collaborating with the development team. Amanda holds a BS degree in Chemistry from the University of Miami. She previously worked at Horizon Discovery, Dharmacon and Thermo Fisher Scientific.

Message Presenter